EDN1 and heart failure: Given the potency of ET-1 as a vasoconstrictor, as well as being a biomarker of endothelial dysfunction and its intricate association with both preeclampsia and cardiovascular disease and heart failure, we expected that the cardio-protective beta-blockers may have reduced its expression.